The need for a national infrastructure to improve the rational use of therapeutics

被引:11
作者
Califf, RM [1 ]
机构
[1] Ctr Educ & Res Therapeut, Durham, NC USA
关键词
Food and Drug Administration; Institute of Medicine; prescription drugs; medical devices; biologies cisapride; troglitazone; rotavirus vaccine; clinical pharmacology; Agency for Healthcare Research and Quality;
D O I
10.1002/pds.699
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The current medical care environment has created expectations that exceed its capabilities, one effect of which has been an increasing awareness of lapses in the quality of healthcare, including medical errors. As more new therapies reach clinical application, the expectations on the part of the public are unlikely to lessen, and yet the ability to assure patients that the benefits of these therapies are known, and that they are without serious side-effects or untoward consequences, eludes the healthcare system. Based on initial experience with a new federal program, the Centers for Education and Research on Therapeutics (CERTs), we propose a national approach to therapeutics education and research, through a public-private partnership that involves academic medical centers, the federal government, industry, and the public. Through a concerted approach, we believe that significant gaps in our understanding of key issues in therapeutics and our ability to educate practitioners, policy makers, and consumers can be significantly enhanced in a manner that could not be achieved without a coordinated approach. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:319 / 327
页数:9
相关论文
共 48 条
  • [1] [Anonymous], MMWR
  • [2] Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction
    Bart, BA
    Gattis, WA
    Diem, SJ
    OConnor, CM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (08) : 1118 - +
  • [3] CALIFF RM, IN PRESS AM J CARDIO
  • [4] Guided medication dosing for inpatients with renal insufficiency
    Chertow, GM
    Lee, J
    Kuperman, GJ
    Burdick, E
    Horsky, J
    Seger, DL
    Lee, R
    Mekala, A
    Song, J
    Komaroff, AL
    Bates, DW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (22): : 2839 - 2844
  • [5] *CTR ED RES THER, 2000, CERTS ANN REP YEAR 1
  • [6] *CTR ED RES THER, 2001, CERTS ANN REP YEAR 2
  • [7] DANZON PM, 2001, HLTH AFF, V20, P96
  • [8] Davidson JRT, 1999, J CLIN PSYCHIAT, V60, P4
  • [9] DAY RS, 1999, OPTIMIZING PATIENT C, P60
  • [10] MORTALITY FOLLOWING VENTRICULAR ARRHYTHMIA SUPPRESSION BY ENCAINIDE, FLECAINIDE, AND MORICIZINE AFTER MYOCARDIAL-INFARCTION - THE ORIGINAL DESIGN CONCEPT OF THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL (CAST)
    EPSTEIN, AE
    HALLSTROM, AP
    ROGERS, WJ
    LIEBSON, PR
    SEALS, AA
    ANDERSON, JL
    COHEN, JD
    CAPONE, RJ
    WYSE, DG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (20): : 2451 - 2455